
The Library
Carnitine palmitoyltransferase 1C : from cognition to cancer
Tools
Casals, Núria, Zammit, Victor A., Herrero, Laura, Fadó, Rut, Rodríguez-Rodríguez, Rosalía and Serra, Dolors (2016) Carnitine palmitoyltransferase 1C : from cognition to cancer. Progress in Lipid Research, 61 . pp. 134-148. doi:10.1016/j.plipres.2015.11.004 ISSN 0163-7827.
|
PDF
WRAP_9577424-ms-050116-casals_zammit_et_al_2016_prog_lipid_res.pdf - Accepted Version - Requires a PDF viewer. Download (1947Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.plipres.2015.11.004
Abstract
Carnitine palmitoyltransferase 1 (CPT1) C was the last member of the CPT1 family of genes to be discovered. CPT1A and CPT1B were identified as the gate-keeper enzymes for the entry of long-chain fatty acids (as carnitine esters) into mitochondria and their further oxidation, and they show differences in their kinetics and tissue expression. Although CPT1C exhibits high sequence similarity to CPT1A and CPT1B, it is specifically expressed in neurons (a cell-type that does not use fatty acids as fuel to any major extent), it is localized in the endoplasmic reticulum of cells, and it has minimal CPT1 catalytic activity with l-carnitine and acyl-CoA esters. The lack of an easily measurable biological activity has hampered attempts to elucidate the cellular and physiological role of CPT1C but has not diminished the interest of the biomedical research community in this CPT1 isoform. The observations that CPT1C binds malonyl-CoA and long-chain acyl-CoA suggest that it is a sensor of lipid metabolism in neurons, where it appears to impact ceramide and triacylglycerol (TAG) metabolism. CPT1C global knock-out mice show a wide range of brain disorders, including impaired cognition and spatial learning, motor deficits, and a deregulation in food intake and energy homeostasis. The first disease-causing CPT1C mutation was recently described in humans, with Cpt1c being identified as the gene causing hereditary spastic paraplegia. The putative role of CPT1C in the regulation of complex-lipid metabolism is supported by the observation that it is highly expressed in certain virulent tumor cells, conferring them resistance to glucose- and oxygen-deprivation. Therefore, CPT1C may be a promising target in the treatment of cancer. Here we review the molecular, biochemical, and structural properties of CPT1C and discuss its potential roles in brain function, and cancer.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||||
Library of Congress Subject Headings (LCSH): | Cancer -- Treatment, Carnitine, Lipids -- Metabolism, Homeostasis | ||||||||||
Journal or Publication Title: | Progress in Lipid Research | ||||||||||
Publisher: | Pergamon Press | ||||||||||
ISSN: | 0163-7827 | ||||||||||
Official Date: | January 2016 | ||||||||||
Dates: |
|
||||||||||
Volume: | 61 | ||||||||||
Page Range: | pp. 134-148 | ||||||||||
DOI: | 10.1016/j.plipres.2015.11.004 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||||
Date of first compliant deposit: | 14 January 2016 | ||||||||||
Date of first compliant Open Access: | 18 December 2016 |
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year